人脑动静脉畸形中KRAS G12D或G12V突变
研究采用数字PCR检测38例人脑动静脉畸形标本中KRAS密码子35的G→A(G12D)和G→T(G12V)突变,并以免役组化验证KRAS G12D蛋白表达。结果检出G→A突变15例(39.5%),G→T突变10例(27.0%),无样本同时阳性,突变主要见于扩张血管内皮细胞。作者认为KRAS功能可能参与BAVM病理生物学并可作为治疗靶点。
要点
- 数字PCR检出KRAS密码子35突变在约三分之二标本中,G12D占39.5%、G12V占27.0%。
- KRAS G12D蛋白主要表达于病灶扩张血管内皮细胞。
- 作者认为KRAS功能可能参与BAVM病理生物学并可作为治疗靶点。
核心结论
- KRAS密码子35突变在约三分之二受检标本中检出,KRAS功能可能主动参与BAVM病理生物学并可作为治疗靶点。
研究设计与样本
- 采用数字PCR分析人脑动静脉畸形石蜡包埋切片提取基因组中KRAS密码子35(G→A,G12D;G→T,G12V)突变,并以免疫组化检测病灶KRAS G12D蛋白表达。
- G→A突变可评估38例样本,G→T突变可评估37例样本。
主要发现
- 检出密码子35 G→A突变15例(39.5%,共38例样本),G→T突变10例(27.0%,共37例样本)。
- 无样本同时阳性 for codon35 G→A和G→T突变。
- 密码子35 G→A突变比例范围为0.60%至12.28%,G→T突变比例范围为1.20%至8.99%。
- 免疫组化显示KRAS G12D突变蛋白主要见于病灶内扩张血管的内皮细胞。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Brain arteriovenous malformations (BAVMs) are vascular malformations composed of tangles of abnormally developed vasculature without capillaries. Abnormal shunting of arteries and veins is formed, resulting in high-pressure vascular channels, which potentially lead to rupture. BAVMs are generally considered a congenital disorder. But clinical evidence regarding involution, regrowth, and de novo formation argue against the static condition of this disease. Recently, the presence of the somatic activating KRAS mutations in more than half of BAVM cases was reported, suggesting the role of KRAS function in the pathogenesis. METHODS: KRAS mutation in codon35 (G→A, G12D; G→T, G12V) was examined by a digital polymerase chain reaction analysis using genome purified from paraffin-embedded slides of human BAVMs. We also examined protein expression of KRAS G12D in lesions to corroborate results from digital polymerase chain reaction analysis. RESULTS: We detected codon35 G→A mutation in 15 (39.5%) among 38 samples and codon35 G→T mutation in 10 (27.0%) among 37 samples we could assess mutations. There were no samples positive for both codon35 G→A and G→T mutation. The ratio of codon35 G→A mutation ranged from 0.60% to 12.28% and that of G→T was from 1.20% to 8.99%. We next examined protein expression of KRAS G12D in BAVM lesions in immunohistochemistry. A KRAS G12D mutant was detected mainly in endothelial cells of dilated vessels in lesions. CONCLUSIONS: KRAS mutations in codon35 were detected in about two thirds of specimens examined. KRAS function may actively contribute to the pathobiology of BAVM and can become a therapeutic target.
引用
- Oka M, Kushamae M, Aoki T, et al. KRAS G12D or G12V Mutation in Human Brain Arteriovenous Malformations. World Neurosurg. 2019. PMID: 30902772. doi:10.1016/j.wneu.2019.03.105
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。